Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions

Serretta, Vincenzo; Galuffo, Antonino; Pavone, Carlo; Allegro, Rosalinda; Pavone‐Macaluso, M.

doi:10.1016/j.urology.2004.08.027

Cited by 41 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other intravesical agents under investigation include gemcitabine, which has been shown to have high response rates, but short disease-free intervals [41][42][43][44][45][46][47]. Additional phase I/II studies [48][49][50] of intravesical gemcitabine published this year confirm these results.…”

Section: Intravesical Therapymentioning

confidence: 93%

Bladder cancer

Barocas

Clark

2008

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

Section: Intravesical Therapymentioning

confidence: 93%

Bladder cancer

Barocas

Clark

2008

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Therefore, gemcitabine is a strong candidate for intravesical therapy in SBC patients who are refractory to BCG. [10][11][12][13] However, after intravesical administration of high doses (40 mg/ml) of gemcitabine in saline solution, significant systemic absorption can still cause gastrointestinal, bladder, and bone marrow toxicity, which limits its clinical value.…”

Section: Regular Articlementioning

confidence: 99%

Microemulsions for Intravesical Delivery of Gemcitabine

Tsai

Hsieh

Huang

et al. 2010

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

The objective of this work was to develop a safe and effective delivery vehicle for topical treatment of gemcitabine. The physicochemical properties, drug release rate, drug level in plasma and bladder, and histological changes of tissue after drug administration were investigated. The electrical conductivity, mean size, and viscosity of drug-loaded microemulsions were 0.8-102.0 mS/cm, 116.8-322.5 nm, and 42.9-105.0 cps؋10 3 , respectively. Gemcitabine loaded microemulsions showed a slower and sustained release. After intravesical administration of aqueous control and microemulsions treated, the drug concentrations in plasma were 15.11 mg/ml and 2.81-12.82 mg/ml, respectively, and the accumulation in bladder were 18.27 mg and 9.12-64.16 mg, respectively. Microemulsions slightly decreased the systemic absorption and significantly enhanced the accumulation in bladder tissue. Moreover, the preliminary toxicity studies revealed no overt adverse histological changes or tissue irritation by the microemulsion application. Therefore, the microemulsions were suggested to be a promising drug carrier for intravesical chemotherapy.

show abstract

“…Most studies focused on its potential use in a second-line setting after failing primary therapy with BCG. Recent trials in the last year included a phase I/II trial using marker lesions that found a regimen of 6-weekly instillations was well tolerated and resulted in a complete response in the marker lesions in 23% and a partial response in 22% [31]. Similar results were found in another phase II study of 26 patients in which 50% of patients had a response to treatment [33].…”

Section: Intravesical Therapymentioning

confidence: 64%

“…Considerable interest has been growing with the use of gemcitabine as an intravesical agent for superficial bladder cancer [31][32][33][34][35][36][37]. Most studies focused on its potential use in a second-line setting after failing primary therapy with BCG.…”

Section: Intravesical Therapymentioning

confidence: 99%

Bladder cancer

Gwynn

Clark

2006

Current Opinion in Oncology

View full text Add to dashboard Cite

The detection of bladder cancer continues to rely on direct visualization with cystoscopy. Efforts are underway to improve the utility of urinary markers and cystoscopy through fluorescence endoscopy. The management of superficial bladder cancer is based on transurethral resection of the tumor with perioperative intravesical instillation of chemotherapy strongly suggested for most patients. Risk stratifying patients with high-risk superficial bladder cancer remain a challenge and area of future research.

show abstract

Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions

Cited by 41 publications

References 9 publications

Bladder cancer

Bladder cancer

Microemulsions for Intravesical Delivery of Gemcitabine

Bladder cancer

Contact Info

Product

Resources

About